Doug Paul

Company: NephKey

Job title: Board

Seminars:

Panel Discussion | Navigating Payers Perspectives & Moving Towards Surrogate Endpoints to Demonstrate Reimbursement for CKD Patient Populations 1:00 pm

How important is having hard outcomes data vs a surrogate measure of CKD progression or improvement? What will it take to pivot away from hard endpoints to demonstrate convincing evidence of improvements in renal function? What are the clinical evidence requirements from payers and insurers to demonstrate reimbursement and offer effective therapies to CKD patients…Read more

day: Day 2 Track 3 PM